• Decrease
  • Normal
  • Increase
U.S. Department of Health and Human Services

About FDA

FDA-TRACK Archive

The list below provides information on FDA’s performance measures and projects as aligned to FDA strategic priorities and program offices. This list enables you to view charts of performance data and progress on important projects and programs.

To view current FDA-TRACK performance measures and projects view the Active Index

Filter








Results

Number of results: 13

ItemProgramOfficeFY
Completed
Strategic PlanStrategic Goal/Area
12012 Small Clinical Trials CourseOSMPOffice of Orphan Products Development2012N/AN/A
2Membership and RecruitmentOSMPAdvisory Committee Oversight and Management Staff2011N/AN/A
3FY 2010 "Do a Designation" WorkshopOSMPOffice of Orphan Products Development2011N/AN/A
4Orphan Drug Designation Standard Operating Policy and Procedure (SOPP)OSMPOffice of Orphan Products Development2011N/AN/A
5Summary Report on the Pediatric Device Consortia Grant ProgramOSMPOffice of Orphan Products Development2011N/AN/A
6Humanitarian Use Device (HUD) GuidanceOSMPOffice of Orphan Products Development2012N/AN/A
7Use of Extrapolation of Efficacy in Products Granted Pediatric ExclusivityOSMPOffice of Pediatric Therapeutics2010N/AN/A
8Use of Alternative Endpoints in Pediatric Clinical TrialsOSMPOffice of Pediatric Therapeutics2012N/AN/A
9Number of presentations/participation at U.S. conferences, stakeholder meetings, and trainings during the monthOSMPOffice of Special Medical Programs2013N/AN/A
10Number of international outreach efforts during the monthOSMPOffice of Special Medical Programs2013N/AN/A
11Total number of inquiries received by OGCP within the monthOSMPOffice of Good Clinical Practice2012N/AN/A
12Percentage of orphan drug designation reviews completed in 120 days or lessOSMPOffice of Orphan Products Development2013N/AN/A
13Grants Review WebsiteOSMPOffice of Orphan Products Development2014N/AN/A

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information in the Archive Index may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.